Drugs / HIV gp120/NefTat/AS02A Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00117429 | Jun 2005 → Sep 2007 | HIV infectious disease | Marcus Altfeld, M.D., Ph.D. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIV gp120/NefTat/AS02A Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00117429 ↗ |
| Modality | Vaccine | “gp120/NefTat/AS02A vaccine candidate” NCT00117429 ↗ |
| Route | Intramuscular | “Injections will be administered IM at weeks 0, 4, and 12.” NCT00117429 ↗ |